US Oncology Research, The US Oncology Network, and Ontada Announce Data Presentations in Critical Need Areas at American Society of Hematology 2021 Annual Meeting and Exhibition

0


THE WOODS, Texas – (COMMERCIAL THREAD) – The investigators of Oncology Research in the United States, The American Oncology Network (The Network), and OntarioMT will share the results of more than 30 studies exploring areas such as diffuse large B-cell lymphoma, non-Hodgkin lymphoma, multiple myeloma, and the management of hematologic adverse events in community oncology at the 63rd American Society of ‘hematology (ASH) Annual meeting and exhibition. The ASH Annual Meeting, a premier scientific event in both malignant and non-malignant hematology, will take place in Atlanta, Georgia, and virtually from December 11-14, 2021.

“We are making tremendous progress in the management of a wide range of hematologic malignancies, including difficult-to-treat blood cancers, and have much more to offer to patients than in the past. However, progress is still needed, ”said Robert L. Coleman, MD, FACOG, FACS, Scientific Director, US Oncology Research. “We are excited to present our latest findings and to come back with the community as we continue to learn, collaborate and innovate to improve patient outcomes. ”

In a late-breaking summaries session on Tuesday, Dec. 14 from 9:00 a.m. to 10:30 a.m.ET, results will be presented from “The POLARIX study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in patients with diffuse large lymphoma BC not previously treated. “

“About 40 percent of patients with newly diagnosed diffuse large B-cell lymphoma are not cured with the current standard of care regimen known as R-CHOP,” said study co-author . John Burke, MD, a hematologist with Rocky Mountain Cancer Centers, a practice of the Network. “In the Phase 3 POLARIX study, we compared a combination of the antibody-drug conjugate targeting CD79b, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone, or pola-R-CHP, with R-CHOP. The results of the POLARIX study may have important implications for how we treat diffuse large B cell lymphoma in the first line setting in the future and we look forward to the results being shared at the meeting. ASH. ”

In addition, Dr Burke will present a summary entitled “Efficacy and Safety of Umbralisib, Ublituximab (U2) and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),»In an oral presentation on Sunday 12 December at 5.30 pm.

“Patients with relapsed or refractory LDGCB generally have a poor prognosis, particularly if they are not candidates for autologous stem cell transplantation or if they relapse after approved CAR-T therapies. In the UNITY-NHL study, we systematically explored the efficacy and tolerability of the PI3K-d / CK1-e inhibitor, umbralisib, alone and in combination with oblituximab, a modified anti-CD20 monoclonal antibody. by glycoengineering, followed by a cohort treated with umbralisib, ublituximab and bendamustine, ”said lead author Dr Burke. “We found that the triple regimen was effective and well tolerated in patients with relapse or refractory LDGCB who were unsuitable for transplant or who had relapsed after transplant. ”

During an oral summary session on Monday December 13 at 4:45 p.m., the results of the study will be presented: “Magnify Completed Induction Phase Analysis: Phase 3b study of lenalidomide + rituximab (R2) followed by maintenance therapy in relapsed / refractory indolent non-Hodgkin lymphoma. ”

“Unfortunately, people with relapsing indolent non-Hodgkin’s lymphoma have limited standard treatment options,” said the study co-author. David Andorsky, MD, hematologist at Rocky Mountain Cancer Centers. “Therefore, our review of the induction phase of the Phase 3b MAGNIFY trial, which provides additional evidence that lenalidomide in combination with rituximab is active with a tolerable safety profile in a wide range of patients with relapsing or refractory disease is encouraging. ”

Jérôme Goldschmidt, MD, oncologist at Blue Ridge Cancer Care, a practice of the Network, will present the results in a poster presentation entitled “Understand the management of hematologic adverse events through the use of healthcare resources, costs, and treatment regimens for patients with extended stage small cell lung cancer treated in community oncology Saturday 11 December from 5.30 p.m. to 7.30 p.m. Lead author of the abstract, Dr. Goldschmidt, worked with Ontario researchers on this observational retrospective study. Ontada is a real-world oncology data and evidence, clinical education and technology provider company dedicated to improving the lives of cancer patients.

“Our study revealed that there is a significant burden of myelosuppressive hematologic adverse events in patients with extended stage small cell lung cancer in the community oncology setting. Notably, patients with grade ≥3 hematologic adverse events appear to have more dose reductions, delays in treatment and use of health services than those without, ”said Dr Goldschmidt. “Future research should strive to understand the full scope of the management of hematologic adverse events and to define the role that therapies that protect the bone marrow from these adverse events can play in reducing this burden. ”

Robert Rifkin, MD, medical director of biosimilars for McKesson, associate chair of hematology research and head of myeloma disease for The US Oncology Network, and hematologist with Rocky Mountain Cancer Centers, co-authored a review of outcomes in people with refractory triple-class multiple myeloma titled: “Real-world treatment models and clinical, economic, and humanistic burden in three-class refractory multiple myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry. “The oral presentation will take place on Saturday December 11 at 10:00 am.

“Resistance to treatment remains a challenge for most patients with multiple myeloma and their health outcomes and quality of life deteriorate with each line of treatment. Patients refractory to immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies, or triple-class refractory, have a particularly poor prognosis and a high disease burden, ”said Dr Rifkin. “Data presented from the current Connect prospection® The MM Disease Registry confirms that people with refractory triple-class multiple myeloma experience poor survival, significant hospitalizations, and clinically significant decline in health-related quality of life, and suggests that new, tolerable therapeutic agents and effective drugs are urgently needed to address the disease burden in refractory triple myeloma.

The full schedule of Affiliate Data Presentations, including the schedule and author information, can be found here. For more information or to interview a trial researcher, contact Claire Crye at 281.825.9927 or [email protected] or Edie DeVine at 209.814.9564 or [email protected]

###

About Oncology Research in the United States

Oncology Research in the United States relies on a network of experienced investigators and dedicated clinical staff who specialize in clinical trials in oncology. US Oncology Research serves approximately 60 research sites and over 165 sites, managing approximately 400 active trials at any given time. Over the past 20 years, Doctors in the Research Network have recruited over 85,000 patients in over 1,600 trials and have been involved in over 100 FDA-approved cancer therapies. Oncology research in the United States is supported by McKesson Company.

About the American Oncology Network

Everyday, The American Oncology Network (The Network) helps approximately 1,400 independent physicians deliver integrated, value-based care to patients – close to home. Through the Network, these independent physicians come together to form a community of expertise and shared resources dedicated to advancing local cancer care and improving patient outcomes. The network provides firms with access to coordinated resources, best business practices, as well as the experience, infrastructure and support of McKesson Company. This collaboration allows Network providers to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

About Ontario

OntarioMT is a real-world oncology data and evidence, clinical education and technology provider company dedicated to transforming cancer control. Part of McKesson Company, we support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community-based oncology providers, and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information visit ontada.com or follow @OntadaOncology.



Share.

Comments are closed.